Zobrazeno 1 - 2
of 2
pro vyhledávání: '"L. Perrotat"'
Autor:
C. A. Isnardi, K. Roberts, R. Quintana, J. Kreimer, C. Echeverria, P. C. Luna, B. M. Virasoro, I. E. Exeni, N. Kogan, M. D. L. A. Correa, D. A. Pereira, D. Zelaya, Y. Tissera, C. Pisoni, M. S. Gálvez Elkin, C. G. Alonso, A. K. Cogo, M. Cosatti, L. Garcia, C. Retamozo, M. Severina, R. Nieto, M. Rosemffet, E. D. Mussano, A. Bertoli, M. Delavega, V. Savio, V. Cosentino, B. Roldan, H. Maldonado Ficco, P. Maid, C. Calle Montoro, L. Fernandez, M. L. Leguizamón, A. B. Gómez Vara, M. A. Alfaro, M. Landi, N. Herscovich, C. Maldini, S. S. De la Vega Fernandez, E. Velozo, P. Giorgis, M. E. Sattler, C. Reyes Gómez, L. Perrotat, C. Reimundes, R. A. Ezquer, V. Saurit, J. Flores Trejo, O. L. Cerda, M. G. Crespo Rocha, V. Carrizo Abarza, I. Strusberg, R. Rojas Tessel, G. Verna, J. M. Bande, P. Farfan, G. Berbotto, G. Pons-Estel, E. E. Schneeberger
Publikováno v:
Annals of the Rheumatic Diseases. 81:1665.2-1666
BackgroundCurrently there is little information on the efficacy and safety of SARS-CoV-2 vaccination in patients with immune-mediated diseases and/or under immunosuppressive treatment in our country, where different types of vaccines and mix regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::818112724fc89a71e6d4ab06c50135e7
https://doi.org/10.1136/annrheumdis-2022-eular.876
https://doi.org/10.1136/annrheumdis-2022-eular.876
Autor:
M. Cosatti, M. E. D´ Angelo, I. E. Petkovic, N. Kogan, D. A. Pereira, Y. Tissera, M. V. Toledo, C. G. Alonso, L. Garcia, M. Severina, M. Rosemffet, A. Bertoli, M. Delavega, V. Cosentino, H. Maldonado Ficco, C. Calle Montoro, S. S. De la Vega Fernandez, G. Berbotto, A. Rollano Perasso, A. B. Gómez Vara, M. Landi, E. Velozo, M. E. Sattler, L. Perrotat, R. A. Ezquer, J. Flores Trejo, P. Farfan, R. Rojas Tessel, V. Carrizo Abarza, J. M. Bande, B. Hernandez, M. J. Papagno, L. A. Rodriguez, V. Martin Koller, F. Montoya, J. Kreimer, P. C. Luna, C. Echeverria, B. M. Virasoro, K. Roberts, C. A. Isnardi, E. E. Schneeberger, G. Pons-Estel, C. Pisoni
Publikováno v:
Annals of the Rheumatic Diseases. 81:929.1-929
BackgroundPatients with rheumatic diseases (RD) have been excluded from SARS-CoV-2 vaccine trials, though data appear to show safety and efficacy, mostly evidence remains in mRNA vaccines. In our country, adenovirus-vector, inactivated and heterologo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e0ebe81d2ede2bb5acb911880c09f7e
https://doi.org/10.1136/annrheumdis-2022-eular.796
https://doi.org/10.1136/annrheumdis-2022-eular.796